Form 4: Neurocrine Biosciences Chief Scientific Officer Executes Pre-Planned Stock Option Exercise and Share Sale

Neurocrine Biosciences' Chief Scientific Officer, Jude Onyia, exercised stock options and subsequently sold an equivalent number of common shares on July 2, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jude Onyia, Chief Scientific Officer of Neurocrine Biosciences Inc. (NBIX), engaged in transactions on July 2, 2025.
• Exercised 20,362 non-qualified stock options at an exercise price of $84.74 per share.
• Immediately sold 20,362 shares of common stock at a weighted average price of $130.1315 per share, with prices ranging from $130.00 to $130.40.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2024, which cannot be amended or modified per issuer policy.
• Following these transactions, Jude Onyia directly beneficially owns 18,289 shares of common stock and 95,087 non-qualified stock options.
• The common stock holdings include 200 shares purchased on February 28, 2025, through the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
• The exercised options were part of a grant where 1/4th vested on November 29, 2022, and an additional 1/48th vests monthly thereafter, with an expiration date of November 29, 2031.

Sentiment

Score: 7

Explanation: The filing indicates a routine, pre-planned insider transaction (option exercise and sale) which is generally neutral to slightly positive as it demonstrates the executive realizing value from their compensation, while the 10b5-1 plan mitigates negative interpretations of the sale. The executive retains significant equity holdings.

Positives

• The exercise of stock options indicates the realization of value from previously granted equity incentives.
• The sale price of $130.1315 per share is significantly higher than the exercise price of $84.74, indicating a profitable transaction for the reporting person.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which demonstrates a structured approach to insider trading and reduces concerns about opportunistic selling.
• The reporting person still holds 18,289 shares of common stock and 95,087 unexercised options, indicating continued alignment with shareholder interests.
• Inclusion of 200 shares purchased through the Employee Stock Purchase Plan on February 28, 2025, shows ongoing participation in employee ownership programs.

Negatives

• The sale of 20,362 shares by a Chief Scientific Officer reduces their direct common stock holdings, which could be perceived as a slight decrease in direct equity alignment, although it is part of a pre-planned strategy.

Future Outlook

NA

Management Comments

• The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2024.
• Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Industry Context

This Form 4 filing reflects a routine insider transaction, common across publicly traded companies where executives receive equity compensation. The use of a Rule 10b5-1 plan is a standard practice for insiders to sell shares in a pre-arranged manner, mitigating concerns about trading on material non-public information. This type of transaction does not typically indicate specific industry trends but rather the individual's financial planning and the company's compensation structure.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans for insider stock sales is a widely accepted corporate governance practice, aligning with best practices for transparency and mitigating accusations of insider trading. Many companies, including peers in the biotechnology and pharmaceutical sectors like Biogen Inc. or Gilead Sciences, encourage or mandate such plans for their executives.
• The exercise of stock options and subsequent sale is a common method for executives to monetize their equity compensation, similar to practices observed at companies like Amgen Inc. or Vertex Pharmaceuticals.
• The profit realized from the option exercise ($130.1315 sale price vs. $84.74 exercise price) is typical for long-term equity incentives in a growing company, reflecting the stock's appreciation since the option grant.

Corporate Governance

Related Party Transactions

• The exercise of stock options and subsequent sale of shares by a Chief Scientific Officer constitutes a related party transaction, as it involves an executive of the company.
• The purchase of 200 shares through the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan is also a related party transaction.

Stakeholder Impact

• Shareholders: The sale of shares by an executive, even under a 10b5-1 plan, might be viewed with slight caution, but the pre-planned nature and continued significant holdings mitigate concerns. The profitable exercise of options reflects the company's stock performance.
• Employees: The mention of the Employee Stock Purchase Plan indicates a benefit available to employees, fostering broader employee ownership.
• Management: The transaction reflects the executive's personal financial planning and compensation realization, which is a standard part of executive compensation.

Key Dates

Recommendation

Keywords

Neurocrine Biosciences, NBIX, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Jude Onyia, Chief Scientific Officer, Equity Compensation